Direct anticancer activity of gonadotropin-releasing hormone-III

Sándor Lovas, I. Pályi, B. Vincze, J. Horváth, M. Kovács, I. Mezö, G. Tóth, I. Teplán, R. F. Murphy

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

In previous studies GnRH-III, a variant of the hypothalamic neurohormone GnRH, was isolated from the brain of the sea lamprey and structurally characterized. GnRH-III is a hypothalamic neurohormone in both female and male sea lampreys. In the present work biological activities of GnRH-III in mammalian systems were examined. In superfused rat pituitary cells, GnRH-III at 1 nM to 100 nM neither induced LH-secretion nor inhibited the LH-secretion elicited by native GnRH and elicited LH release only at 1 μM. At high dose (500 μg/day) in vivo, GnRH-III behaved as a GnRH agonist, though, it was 1000-fold less active than ovurelin. The in vitro and in vivo results were in good agreement in showing that GnRH-III is only a weak agonist of the endocrine activity of GnRH. GnRH-III specifically bound to receptors on cancer cells and recognized not only the high-, but also the low-affinity binding sites. GnRH-III significantly suppressed growth of human cancer cells which have GnRH receptors. The inhibitory effect of GnRH-III on growth of cancer cells was specific and direct since the peptide did not have endocrine activity in the concentration range found to be effective in anticancer assays. GnRH-III inhibited equally the growth of ER-positive and -negative breast and TeR-positive and negative prostate cells.

Original languageEnglish
Pages (from-to)384-389
Number of pages6
JournalJournal of Peptide Research
Volume52
Issue number5
StatePublished - 1998

Fingerprint

Gonadotropin-Releasing Hormone
Petromyzon
Cells
Neurotransmitter Agents
Growth
gonadotropin-releasing hormone-III
LHRH Receptors
Neoplasms
Bioactivity
Rats
Prostate
Assays
Brain
Breast
Binding Sites
Peptides

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Endocrinology

Cite this

Lovas, S., Pályi, I., Vincze, B., Horváth, J., Kovács, M., Mezö, I., ... Murphy, R. F. (1998). Direct anticancer activity of gonadotropin-releasing hormone-III. Journal of Peptide Research, 52(5), 384-389.

Direct anticancer activity of gonadotropin-releasing hormone-III. / Lovas, Sándor; Pályi, I.; Vincze, B.; Horváth, J.; Kovács, M.; Mezö, I.; Tóth, G.; Teplán, I.; Murphy, R. F.

In: Journal of Peptide Research, Vol. 52, No. 5, 1998, p. 384-389.

Research output: Contribution to journalArticle

Lovas, S, Pályi, I, Vincze, B, Horváth, J, Kovács, M, Mezö, I, Tóth, G, Teplán, I & Murphy, RF 1998, 'Direct anticancer activity of gonadotropin-releasing hormone-III', Journal of Peptide Research, vol. 52, no. 5, pp. 384-389.
Lovas S, Pályi I, Vincze B, Horváth J, Kovács M, Mezö I et al. Direct anticancer activity of gonadotropin-releasing hormone-III. Journal of Peptide Research. 1998;52(5):384-389.
Lovas, Sándor ; Pályi, I. ; Vincze, B. ; Horváth, J. ; Kovács, M. ; Mezö, I. ; Tóth, G. ; Teplán, I. ; Murphy, R. F. / Direct anticancer activity of gonadotropin-releasing hormone-III. In: Journal of Peptide Research. 1998 ; Vol. 52, No. 5. pp. 384-389.
@article{63b07fe7c07f46e09926d65371f2a12f,
title = "Direct anticancer activity of gonadotropin-releasing hormone-III",
abstract = "In previous studies GnRH-III, a variant of the hypothalamic neurohormone GnRH, was isolated from the brain of the sea lamprey and structurally characterized. GnRH-III is a hypothalamic neurohormone in both female and male sea lampreys. In the present work biological activities of GnRH-III in mammalian systems were examined. In superfused rat pituitary cells, GnRH-III at 1 nM to 100 nM neither induced LH-secretion nor inhibited the LH-secretion elicited by native GnRH and elicited LH release only at 1 μM. At high dose (500 μg/day) in vivo, GnRH-III behaved as a GnRH agonist, though, it was 1000-fold less active than ovurelin. The in vitro and in vivo results were in good agreement in showing that GnRH-III is only a weak agonist of the endocrine activity of GnRH. GnRH-III specifically bound to receptors on cancer cells and recognized not only the high-, but also the low-affinity binding sites. GnRH-III significantly suppressed growth of human cancer cells which have GnRH receptors. The inhibitory effect of GnRH-III on growth of cancer cells was specific and direct since the peptide did not have endocrine activity in the concentration range found to be effective in anticancer assays. GnRH-III inhibited equally the growth of ER-positive and -negative breast and TeR-positive and negative prostate cells.",
author = "S{\'a}ndor Lovas and I. P{\'a}lyi and B. Vincze and J. Horv{\'a}th and M. Kov{\'a}cs and I. Mez{\"o} and G. T{\'o}th and I. Tepl{\'a}n and Murphy, {R. F.}",
year = "1998",
language = "English",
volume = "52",
pages = "384--389",
journal = "Chemical Biology and Drug Design",
issn = "1747-0277",
publisher = "Blackwell",
number = "5",

}

TY - JOUR

T1 - Direct anticancer activity of gonadotropin-releasing hormone-III

AU - Lovas, Sándor

AU - Pályi, I.

AU - Vincze, B.

AU - Horváth, J.

AU - Kovács, M.

AU - Mezö, I.

AU - Tóth, G.

AU - Teplán, I.

AU - Murphy, R. F.

PY - 1998

Y1 - 1998

N2 - In previous studies GnRH-III, a variant of the hypothalamic neurohormone GnRH, was isolated from the brain of the sea lamprey and structurally characterized. GnRH-III is a hypothalamic neurohormone in both female and male sea lampreys. In the present work biological activities of GnRH-III in mammalian systems were examined. In superfused rat pituitary cells, GnRH-III at 1 nM to 100 nM neither induced LH-secretion nor inhibited the LH-secretion elicited by native GnRH and elicited LH release only at 1 μM. At high dose (500 μg/day) in vivo, GnRH-III behaved as a GnRH agonist, though, it was 1000-fold less active than ovurelin. The in vitro and in vivo results were in good agreement in showing that GnRH-III is only a weak agonist of the endocrine activity of GnRH. GnRH-III specifically bound to receptors on cancer cells and recognized not only the high-, but also the low-affinity binding sites. GnRH-III significantly suppressed growth of human cancer cells which have GnRH receptors. The inhibitory effect of GnRH-III on growth of cancer cells was specific and direct since the peptide did not have endocrine activity in the concentration range found to be effective in anticancer assays. GnRH-III inhibited equally the growth of ER-positive and -negative breast and TeR-positive and negative prostate cells.

AB - In previous studies GnRH-III, a variant of the hypothalamic neurohormone GnRH, was isolated from the brain of the sea lamprey and structurally characterized. GnRH-III is a hypothalamic neurohormone in both female and male sea lampreys. In the present work biological activities of GnRH-III in mammalian systems were examined. In superfused rat pituitary cells, GnRH-III at 1 nM to 100 nM neither induced LH-secretion nor inhibited the LH-secretion elicited by native GnRH and elicited LH release only at 1 μM. At high dose (500 μg/day) in vivo, GnRH-III behaved as a GnRH agonist, though, it was 1000-fold less active than ovurelin. The in vitro and in vivo results were in good agreement in showing that GnRH-III is only a weak agonist of the endocrine activity of GnRH. GnRH-III specifically bound to receptors on cancer cells and recognized not only the high-, but also the low-affinity binding sites. GnRH-III significantly suppressed growth of human cancer cells which have GnRH receptors. The inhibitory effect of GnRH-III on growth of cancer cells was specific and direct since the peptide did not have endocrine activity in the concentration range found to be effective in anticancer assays. GnRH-III inhibited equally the growth of ER-positive and -negative breast and TeR-positive and negative prostate cells.

UR - http://www.scopus.com/inward/record.url?scp=0344141211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344141211&partnerID=8YFLogxK

M3 - Article

VL - 52

SP - 384

EP - 389

JO - Chemical Biology and Drug Design

JF - Chemical Biology and Drug Design

SN - 1747-0277

IS - 5

ER -